CDK4/6抑制剂在激素受体阳性进展期乳腺癌治疗中的研究进展

The progress of therapy with CDK4/6 inhibitors in patients with hormone-receptor positive metastatic breast cancer

内分泌治疗因其兼具良好的疗效及安全性,是激素受体阳性进展期乳腺癌患者的重要治疗手段。近年来内分泌领域进展迅速,很多新型药物相继出现,其中包括多种可以逆转或延迟内分泌耐药的周期蛋白依赖性激酶(cyclin-dependent kinase,CDK)4/6抑制剂。CDK4/6抑制剂联合内分泌治疗可为激素受体阳性进展期乳腺癌患者带来生存获益、延迟至化疗时间,正逐渐改变国内外激素受体阳性进展期乳腺癌的治疗模式。本文将就CDK4/6抑制剂在激素受体阳性进展期乳腺癌中的治疗进展进行综述。

Endocrine therapy is the mainstay for patients with hormone-receptor-positive metastatic breast cancer because of its efficacy and safety.With the development of new and efficacious agents,including cyclin-dependent kinase(CDK)4/6 inhibitors,the options for endocrine therapy have expanded.CDK4/6 inhibitors combined with endocrine therapy have been shown to improve survival and delay the time to chemotherapy in patients with hormone-receptor-positive metastatic breast cancer.Accordingly,the treatment strategies for hormone-receptor-positive metastatic breast cancer are changing around the world.This review aims to summarize and discuss the progress of therapy with CDK4/6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer.